deucrictibant
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Feb 26, 2024 (NCT06343779)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 3 Sponsor(trial)
Indications
Mechanism of action
- Bradykinin B2 receptorANTAGONIST
BDKRB2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
[2H][C@@](C)(NC(=O)COC(F)F)c1cc(F)cc(Cl)c1COc1cccc2c(-c3ncnn3C)cc(C)nc12- Mol. weight
- 534.94 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095059 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266805 | Phase 3 | Oct 16, 2025 | Pharvaris Netherlands B.V. |
| NCT07046806 | Phase 1/Phase 2 (Phase 2) | Mar 10, 2025 | — |
| NCT06669754 | Phase 3 | Dec 31, 2024 | Pharvaris Netherlands B.V. |
| NCT06679881 | Phase 3 | Dec 31, 2024 | Pharvaris Netherlands B.V. |
| NCT06343779 | Phase 3 | Feb 26, 2024 | Pharvaris Netherlands B.V. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pharvaris Netherlands B.V. | For profit | 4 | 4 | 1 | 2024 |
1 organizations
Page 1 / 1